Broadly neutralizing antibodies (bNAbs) offer promising opportunities for preventing HIV-1 infection in humans. Immunoprophylaxis with potent bNAbs efficiently protects non-human primates from mucosal transmission even after repeated challenges. However, the precise mechanisms of bNAb-mediated viral inhibition in mucosal tissues are currently unknown. Here, we show that immunoglobulin (Ig)G and IgA bNAbs do not interfere with the endocytic transport of HIV-1 across epithelial cells, a process referred to as transcytosis. Instead, both viruses and antibodies are translocated to the basal pole of epithelial cells, possibly in the form of an immune complex. Importantly, as opposed to free virions, viral particles bound by bNAbs are no longer infectious after transepithelial transit. Post-transcytosis neutralization activity of bNAbs displays comparable inhibitory concentrations as those measured in classical neutralization assays. Thus, bNAbs do not block the transport of incoming HIV-1 viruses across the mucosal epithelium but rather neutralize the transcytosed virions, highlighting their efficient prophylactic and protective activity in vivo.
Broadly neutralizing antibodies suppress post-transcytosis HIV-1 infectivity
V. Lorin,V. Lorin,V. Lorin,M. Malbec,M. Malbec,C. Eden,C. Eden,Timothée Bruel,Timothée Bruel,F. Porrot,F. Porrot,Michael S Seaman,Olivier Schwartz,Olivier Schwartz,H. Mouquet,H. Mouquet
Published 2016 in Mucosal Immunology
ABSTRACT
PUBLICATION RECORD
- Publication year
2016
- Venue
Mucosal Immunology
- Publication date
2016-12-14
- Fields of study
Biology, Medicine
- Identifiers
- External record
- Source metadata
Semantic Scholar, PubMed
CITATION MAP
EXTRACTION MAP
CLAIMS
- No claims are published for this paper.
CONCEPTS
- No concepts are published for this paper.
REFERENCES
Showing 1-89 of 89 references · Page 1 of 1
CITED BY
Showing 1-12 of 12 citing papers · Page 1 of 1